Development of Hodgkin's disease in a patient receiving procarbazine, CCNU, and vincristine therapy for a gemistocytic astrocytoma.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001254:Astrocytoma / Q000628:therapy*; D001932:Brain Neoplasms / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000139:chemically induced*; D006801:Humans; D008130:Lomustine / Q000009:adverse effects; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000139:chemically induced*; D011344:Procarbazine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D000970:Antineoplastic Agents; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine